venBio Global Strategic Fund IV, L.P.
SEC Form 4 insider trading activity
venBio Global Strategic Fund IV, L.P. has filed 1 SEC Form 4 filing (4 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Aug 10, 2026.
On the most recent filing, venBio Global Strategic Fund IV, L.P. is listed as 10% Owner at Attovia Therapeutics, Inc. Inside the rolling window, venBio Global Strategic Fund IV, L.P. reported 1 open-market purchase totaling $6.5M in ATTO and no open-market sales.
Companies traded
Other insiders at ATTO
Insider Buying
$6.5M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has venBio Global Strategic Fund IV, L.P. made?
venBio Global Strategic Fund IV, L.P. has filed 1 SEC Form 4 filing (4 transaction rows) across 1 company since 2026.
Which companies does venBio Global Strategic Fund IV, L.P. trade?
venBio Global Strategic Fund IV, L.P. has filed SEC Form 4 disclosures for 1 company, including ATTO.
When was venBio Global Strategic Fund IV, L.P.'s most recent SEC Form 4 filing?
venBio Global Strategic Fund IV, L.P.'s most recent SEC Form 4 filing on Tracefour is dated Aug 10, 2026.
What is venBio Global Strategic Fund IV, L.P.'s total buy and sell value in the current window?
Inside the rolling retention window, venBio Global Strategic Fund IV, L.P. bought $6.5M and sold $0 based on SEC Form 4 filings.
What was venBio Global Strategic Fund IV, L.P.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 382,352 ATTO shares on 2026-08-06, worth $6.5M, per SEC Form 4 filings.